Aclidinium bromide (BioDeep_00000752559)

   


代谢物信息卡片


Aclidinium bromide

化学式: C26H30BrNO4S2 (563.079952)
中文名称: 阿地溴铵
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: C1C[N+]2(CCC1C(C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5.[Br-]
InChI: 1H/q+1

描述信息

R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03B - Other drugs for obstructive airway diseases, inhalants > R03BB - Anticholinergics
C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent
Aclidinium Bromide (LAS 34273; LAS-W 330) is a long-acting, inhaled muscarinic antagonist. Aclidinium Bromide has the potential for chronic obstructive pulmonary disease (COPD) research[1][2][3][4].

同义名列表

4 个代谢物同义名

Aclidinium bromide; LAS 34273; LAS-W 330; Aclidinium (Bromide)



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Marco Contoli, Paolo Solidoro, Fabiano Di Marco, Nicola Scichilone, Angelo Corsico, Fulvio Braido, Pierachille Santus. Effects of aclidinium on determinants of COPD severity: symptoms and quality of life. International journal of chronic obstructive pulmonary disease. 2016; 11(?):3043-3050. doi: 10.2147/copd.s122433. [PMID: 27980401]
  • Amadeu Gavaldà, Israel Ramos, Carla Carcasona, Elena Calama, Raquel Otal, José Luis Montero, Sonia Sentellas, Monica Aparici, Dolors Vilella, Joan Alberti, Jorge Beleta, Montserrat Miralpeix. The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide. Pulmonary pharmacology & therapeutics. 2014 Aug; 28(2):114-21. doi: 10.1016/j.pupt.2014.05.005. [PMID: 24928173]
  • Antonio Mete, Keith Bowers, Richard J Bull, Helen Coope, David K Donald, Katherine J Escott, Rhonan Ford, Ken Grime, Andrew Mather, Nicholas C Ray, Vince Russell. The design of a novel series of muscarinic receptor antagonists leading to AZD8683, a potential inhaled treatment for COPD. Bioorganic & medicinal chemistry letters. 2013 Dec; 23(23):6248-53. doi: 10.1016/j.bmcl.2013.09.092. [PMID: 24144851]
  • François Maltais, Julie Milot. The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease. Therapeutic advances in respiratory disease. 2012 Dec; 6(6):345-61. doi: 10.1177/1753465812463626. [PMID: 23075544]
  • Vandana Gupta, Dave Singh. Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Expert review of respiratory medicine. 2012 Dec; 6(6):581-8. doi: 10.1586/ers.12.61. [PMID: 23234445]
  • G F Joos. Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Drugs of today (Barcelona, Spain : 1998). 2012 Dec; 48(12):757-63. doi: 10.1358/dot.2012.48.12.1885871. [PMID: 23243632]
  • Stephan de la Motte, Jutta Beier, Karin Schmid, Silvia Pascual, Josep Maria Jansat, Esther Garcia Gil. Pharmacokinetics and safety of aclidinium bromide in younger and elderly patients with chronic obstructive pulmonary disease. International journal of clinical pharmacology and therapeutics. 2012 Jun; 50(6):403-12. doi: 10.5414/cp201628. [PMID: 22541745]
  • Stephan Ortiz, Stephen Flach, Cynthia Caracta, Esther Garcia Gil, Josep M Jansat. Safety and tolerability of aclidinium administered intravenously and absolute bioavailability of inhaled aclidinium in healthy male participants. Journal of clinical pharmacology. 2012 Jun; 52(6):819-27. doi: 10.1177/0091270011406281. [PMID: 21628603]
  • K Lasseter, S Dilzer, J M Jansat, E Garcia Gil, C F Caracta, S Ortiz. Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers. Pulmonary pharmacology & therapeutics. 2012 Apr; 25(2):193-9. doi: 10.1016/j.pupt.2012.02.002. [PMID: 22366196]
  • Amadeu Gavaldà, Jordi Gras, Josep Llupià, Jordi Aubets, Jorge Beleta, Jesús Llenas. Aclidinium bromide, a novel long-acting muscarinic antagonist for COPD with improved preclinical renal and urinary safety profile. Life sciences. 2012 Feb; 90(7-8):301-5. doi: 10.1016/j.lfs.2011.12.002. [PMID: 22213116]
  • Stephan Ortiz, Stephen Flach, John Ho, Fanying Li, Cynthia F Caracta, Esther Garcia Gil, Josep M Jansat. Mass balance and metabolism of aclidinium bromide following intravenous administration of [¹⁴C]-aclidinium bromide in healthy subjects. Biopharmaceutics & drug disposition. 2012 Jan; 33(1):39-45. doi: 10.1002/bdd.1773. [PMID: 22275272]
  • Kenneth C Lasseter, Jordi Aubets, Ferran Chuecos, Esther Garcia Gil. Aclidinium bromide, a long-acting antimuscarinic, does not affect QT interval in healthy subjects. Journal of clinical pharmacology. 2011 Jun; 51(6):923-32. doi: 10.1177/0091270010374471. [PMID: 20959525]
  • Khuder Alagha, Arnaud Bourdin, Céline Tummino, Pascal Chanez. An update on the efficacy and safety of aclidinium bromide in patients with COPD. Therapeutic advances in respiratory disease. 2011 Feb; 5(1):19-28. doi: 10.1177/1753465810381546. [PMID: 20884687]
  • Karin Schmid, Silvia Pascual, Esther Garcia Gil, Stephan Ortiz, Josep M Jansat. Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: A phase I, open-label, single-dose clinical trial. Clinical therapeutics. 2010 Sep; 32(10):1798-812. doi: 10.1016/j.clinthera.2010.09.002. [PMID: 21194604]
  • Joan Albertí, Audrey Martinet, Sònia Sentellas, Miquel Salvà. Identification of the human enzymes responsible for the enzymatic hydrolysis of aclidinium bromide. Drug metabolism and disposition: the biological fate of chemicals. 2010 Jul; 38(7):1202-10. doi: 10.1124/dmd.109.031724. [PMID: 20332199]
  • G F Joos, V J Schelfhout, R A Pauwels, F Kanniess, H Magnussen, R Lamarca, J M Jansat, E Garcia Gil. Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients. Respiratory medicine. 2010 Jun; 104(6):865-72. doi: 10.1016/j.rmed.2009.12.003. [PMID: 20044242]
  • Vanessa J Schelfhout, Pau Ferrer, Josep Maria Jansat, Francesc Peris, Esther Garcia Gil, Romain A Pauwels, Guy F Joos. Activity of aclidinium bromide, a new long-acting muscarinic antagonist: a phase I study. British journal of clinical pharmacology. 2010 May; 69(5):458-64. doi: 10.1111/j.1365-2125.2010.03622.x. [PMID: 20573081]
  • Sonia Sentellas, Israel Ramos, Joan Albertí, Miquel Salvà, Francisca Antón, Montserrat Miralpeix, Jorge Beleta, Amadeu Gavaldà. Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2010 Mar; 39(5):283-90. doi: 10.1016/j.ejps.2010.01.004. [PMID: 20093184]
  • Josep M Jansat, Rosa Lamarca, Gonzalo de Miquel, Andreas Schrödter, Barbara Miletzki, Matthias Gurniak. Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants. Journal of clinical pharmacology. 2009 Oct; 49(10):1239-46. doi: 10.1177/0091270009336353. [PMID: 19592595]
  • María Prat, Dolors Fernández, M Antonia Buil, María I Crespo, Gaspar Casals, Manuel Ferrer, Laia Tort, Jordi Castro, Juan M Monleón, Amadeu Gavaldà, Montserrat Miralpeix, Israel Ramos, Teresa Doménech, Dolors Vilella, Francisca Antón, Josep M Huerta, Sonia Espinosa, Manuel López, Sonia Sentellas, Marisa González, Joan Albertí, Victor Segarra, Alvaro Cárdenas, Jorge Beleta, Hamish Ryder. Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-{[hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide (aclidinium bromide). Journal of medicinal chemistry. 2009 Aug; 52(16):5076-92. doi: 10.1021/jm900132z. [PMID: 19653626]
  • J M Jansat, R Lamarca, E Garcia Gil, P Ferrer. Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects. International journal of clinical pharmacology and therapeutics. 2009 Jul; 47(7):460-8. doi: 10.5414/cpp47460. [PMID: 19640353]
  • Mario Cazzola. Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD. Current opinion in investigational drugs (London, England : 2000). 2009 May; 10(5):482-90. doi: NULL. [PMID: 19431081]